DataSheet3_Refining dual RNA-seq mapping: sequential and combined approaches in host-parasitic plant dynamics.csv by Carmine Fruggiero (20143830)

“…<p>Transcriptional profiling in host plant-parasitic plant interactions is challenging due to the tight interface between host and parasitic plants and the percentage of homologous sequences shared. …”

DataSheet12_Refining dual RNA-seq mapping: sequential and combined approaches in host-parasitic plant dynamics.csv by Carmine Fruggiero (20143830)

“…<p>Transcriptional profiling in host plant-parasitic plant interactions is challenging due to the tight interface between host and parasitic plants and the percentage of homologous sequences shared. …”

DataSheet6_Refining dual RNA-seq mapping: sequential and combined approaches in host-parasitic plant dynamics.csv by Carmine Fruggiero (20143830)

“…<p>Transcriptional profiling in host plant-parasitic plant interactions is challenging due to the tight interface between host and parasitic plants and the percentage of homologous sequences shared. …”

Error-Bar graph. by Haichao Li (225035)

“…Results show that SIDFM reduces navigation errors by 12.09% at low acceleration and 11.43% at high acceleration while also significantly decreasing positioning errors. These improvements enhance the stability, precision, and safety of AGVs in dynamic manufacturing environments. …”

DataSheet7_Refining dual RNA-seq mapping: sequential and combined approaches in host-parasitic plant dynamics.csv by Carmine Fruggiero (20143830)

“…<p>Transcriptional profiling in host plant-parasitic plant interactions is challenging due to the tight interface between host and parasitic plants and the percentage of homologous sequences shared. …”

DataSheet9_Refining dual RNA-seq mapping: sequential and combined approaches in host-parasitic plant dynamics.csv by Carmine Fruggiero (20143830)

“…<p>Transcriptional profiling in host plant-parasitic plant interactions is challenging due to the tight interface between host and parasitic plants and the percentage of homologous sequences shared. …”

raw data for GCB paper.xlsx by Dongming Wang (21443882)

“…However, risks include decreasing soil phosphate (P) availability and intensifying greenhouse gas emissions (methane [CH₄], nitrous oxide [N₂O]), challenging food security sustainability. …”

Image 1_TSLP pretreatment inhibits M1 macrophage polarization and attenuates LPS-induced iNKT cell-dependent acute lung injury.pdf by Ting Zhou (38572)

“…In addition, TSLP treatment significantly inhibited M1 macrophage polarization and promoted M2 macrophage differentiation. …”

Supplementary Material for: Retrospective Analysis of Allergen Characteristics in Patients with Allergic Diseases in Sanmen, Zhejiang Province by figshare admin karger (2628495)

“…Objective: Allergic diseases represent a growing global health challenge, necessitating region-specific allergen characterization for targeted prevention and treatment. …”

supplementary figure: Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma by Takuto Itano (16830105)

“…The RT‒PCR data are presented as the means ± SDs (n = 3). Statistical significance: ns, p ≥ 0.05. …”

Data Sheet 1_Case Report: Late diagnosis of McCune-Albright with severe kyphoscoliosis, acromegaly and tertiary hyperparathyroidism.pdf by Anna Bogusławska (20293545)

“…Genetic confirmation of MAS can be challenging.</p>…”

Table 1_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Supplementary file 1_Burden of ageing spectrum of diseases in China, 1990–2021: a systematic analysis of global burden of disease study 2021.pdf by Li Yang (6520)

“…Background<p>Population aging represents a pressing challenge for China, given its vast population and the growing proportion of adults aged 65 years and older. …”

Data Sheet 1_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.pdf by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 2_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 3_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Behavior is best fit by models with independent attributes. by Aster Q. Perkins (22008260)

“…Bars show across-session means, circles show values from individual sessions. …”

Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”